RO7020531

DRUG2 trials

Sponsors

Hoffmann-La Roche

Conditions

Healthy ParticipantsHepatitis B, Chronic

Phase 1

A Study in Healthy Volunteers and in Participants With Chronic Hepatitis B to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7020531

CompletedNCT02956850

Hoffmann-La RocheHepatitis B, Chronic

Start: 2016-12-12End: 2021-06-15Updated: 2024-02-08

A Study to Assess the Safety and Tolerability of Single and Multiple Ascending Doses of Oral RO7020531 in Chinese Healthy Participants.

CompletedNCT03530917

Hoffmann-La RocheHealthy Participants

Start: 2018-05-15End: 2019-05-15Updated: 2020-07-13

Related Papers

TLR7 agonist RO7020531 versus placebo in healthy volunteers and patients with chronic hepatitis B virus infection: a randomised, observer-blind, placebo-controlled, phase 1 trial.

2022-12-0923 citations